[144] Surgery Partners, Inc. SEC Filing
Surgery Partners, Inc. (SGRY) Form 144 notice reports a planned sale of 18,134 common shares through UBS on 09/29/2025 with an aggregate market value of $399,822. The filer states these shares were acquired the same day via an equity option exercise, and the proposed sale will be executed on NASDAQ. The filing lists extensive insider selling by Wayne DeVeydt over the prior three months totaling 719,604 shares sold across multiple dates, generating cumulative gross proceeds reported in the filing. The company has 128,209,410 shares outstanding, which provides context for the scale of these transactions relative to the float.
Surgery Partners, Inc. (SGRY) Form 144 notice riporta una vendita pianificata di 18.134 azioni ordinarie tramite UBS il 29/09/2025 con un valore di mercato aggregato di 399.822 dollari. Il dichiarante afferma che queste azioni sono state acquisite lo stesso giorno tramite un esercizio di opzione azionaria, e la vendita proposta verrà eseguita su NASDAQ. Il fascicolo elenca una consistente vendita interna da parte di Wayne DeVeydt nei tre mesi precedenti, per un totale di 719.604 azioni vendute in diverse date, che genera proventi lordi cumulativi riportati nel fascicolo. L’azienda ha 128.209.410 azioni in circolazione, fornendo contesto alla scala di queste transazioni rispetto al flottante.
Surgery Partners, Inc. (SGRY) Form 144 notice reporta una venta planificada de 18.134 acciones ordinarias a través de UBS el 29/09/2025 con un valor de mercado agregado de 399.822 dólares. El presentante indica que estas acciones fueron adquiridas el mismo día mediante un ejercicio de opción de acciones, y la venta propuesta se ejecutará en NASDAQ. El archivo/prevención detalla una extensa venta interna por parte de Wayne DeVeydt durante los tres meses previos, que totaliza 719.604 acciones vendidas en varias fechas, generando ingresos brutos acumulados reportados en el trámite. La empresa tiene 128.209.410 acciones en circulación, lo que contextualiza la magnitud de estas transacciones respecto al flotante.
Surgery Partners, Inc. (SGRY) Form 144 공고는 2025년 9월 29일 UBS를 통해 18,134주 보통주를 매도할 계획이며 총 시장가치는 399,822달러라고 보고합니다. 제출자는 이 주식들이 같은 날 주식매수선택권 행사로 취득되었으며 제안된 매도는 NASDAQ에서 실행될 예정이라고 밝힙니다. 제출서는 Wayne DeVeydt의 지난 3개월간의 광범위한 내부자 매도가 여러 날짜에 걸쳐 총 719,604주가 매도되었다고 목록화하고, 이는 보고서에 기재된 누적 총거래수익을 생성합니다. 회사의 발행주식 수는 128,209,410주로, 이러한 거래의 규모를 유통주식 대비 맥락화합니다.
Surgery Partners, Inc. (SGRY) avis Form 144 indique une vente planifiée de 18 134 actions ordinaires via UBS le 29/09/2025 d’une valeur marchande brute de 399 822 dollars. Le déposant indique que ces actions ont été acquises le même jour par exercice d’option d’achat, et la vente proposée sera exécutée sur le NASDAQ. Le dossier répertorie une vente interne étendue par Wayne DeVeydt au cours des trois derniers mois, totalisant 719 604 actions vendues à diverses dates, générant des produits bruts cumulatifs rapportés dans le dossier. L’entreprise compte 128 209 410 actions en circulation, ce qui fournit le contexte de l’ampleur de ces transactions par rapport au flottant.
Surgery Partners, Inc. (SGRY) Form 144 Hinweis meldet einen geplanten Verkauf von 18.134 Stammaktien über UBS am 29.09.2025 mit einem aggregierten Marktwert von 399.822 USD. Der Einreicher erklärt, dass diese Aktien am selben Tag durch eine Ausübung einer Aktienoption erworben wurden und der vorgeschlagene Verkauf an der NASDAQ durchgeführt wird. Die Einreichung listet umfangreiche Insider-Verkäufe von Wayne DeVeydt über die letzten drei Monate auf, insgesamt 719.604 Aktien, die in mehreren Terminen verkauft wurden und in dem Bericht ausgewiesene kumulierte Bruttoerlöse generieren. Das Unternehmen hat 128.209.410 ausstehende Aktien, was den Umfang dieser Transaktionen im Verhältnis zur Free Float-Größe kontextualisiert.
إشعار Form 144 من Surgery Partners, Inc. (SGRY) يورد بيعاً مخططاً لـ 18,134 سهماً عاديًا عبر UBS في 29/09/2025 بقيمة سوقية إجمالية قدرها 399,822 دولاراً. يذكر المستند أن هذه الأسهم تم الحصول عليها في اليوم نفسه من خلال تمرين خيار أسهم، وأن البيع المقترح سيتم تنفيذه على NASDAQ. يListing الوثيقة مبيعات داخلية واسعة من قِبل وين ديڤيـدت خلال الأشهر الثلاثة السابقة بإجمالي 719,604 سهماً بيعت عبر تواريخ متعددة، مما يولد العمولات الإجمالية الإجمالية المعلنة في الوثيقة. تمتلك الشركة 128,209,410 سهماً قائمين، مما يوفر سياقاً لحجم هذه المعاملات بالنسبة للتداول الحر.
Surgery Partners, Inc. (SGRY) Form 144 通知 报告称计划于 2025-09-29 通过 UBS 出售 18,134 股普通股，总代价为 399,822 美元。申报人表示这些股票在同日通过 股票期权行使取得，拟议的出售将于 NASDAQ 进行。该备案列出 Wayne DeVeydt 在过去三个月内的广泛内部人出售，总计 719,604 股，分布在多个日期，产生备案中的累计毛收入。该公司流通在外股数为 128,209,410 股，这为这些交易相对于自由流通股的规模提供了背景。
- Securities were acquired via equity option exercise, indicating the sale follows compensation-related acquisition rather than an external purchase
- Planned sale size ($399,822) is small relative to total shares outstanding (128,209,410), limiting immediate market supply impact from this single transaction
- Substantial insider selling: 719,604 shares sold by Wayne DeVeydt in the past three months, which may concern investors
- Multiple large trades including blocks of 100,000 and 150,000 shares, increasing perceived selling pressure
- No accompanying disclosure of a 10b5-1 trading plan or reasons for sales in the filing text
Insights
TL;DR: Insider sold large volumes recently; this filing not accompanied by company operational data.
The Form 144 shows a director/officer-level seller executing frequent, sizable sales totaling 719,604 shares over three months and a planned sale of 18,134 shares after exercising options. From a market perspective, the planned sale of 18,134 shares ($399,822) is modest relative to 128.2 million shares outstanding, suggesting limited direct supply pressure from this single planned trade. However, the record of repeated large disposals earlier in the period may be interpreted by market participants as liquidity-driven or portfolio rebalancing rather than company-specific news because the filing contains no operational or financial disclosures.
TL;DR: Sustained insider selling raises governance and signaling considerations.
The schedule of numerous transactions by Wayne DeVeydt—including multiple six-figure share disposals—warrants attention from governance stakeholders. Frequent large sales by insiders can prompt questions about personal diversification, exercise-and-sell behavior following option vesting, or the absence of a disclosed 10b5-1 trading plan in this notice. The filing includes a representation that the seller is not aware of undisclosed material information. Absent further context on motivations or trading-plan dates, these repeated sales represent a negative governance signal to some investors.
Surgery Partners, Inc. (SGRY) Form 144 notice riporta una vendita pianificata di 18.134 azioni ordinarie tramite UBS il 29/09/2025 con un valore di mercato aggregato di 399.822 dollari. Il dichiarante afferma che queste azioni sono state acquisite lo stesso giorno tramite un esercizio di opzione azionaria, e la vendita proposta verrà eseguita su NASDAQ. Il fascicolo elenca una consistente vendita interna da parte di Wayne DeVeydt nei tre mesi precedenti, per un totale di 719.604 azioni vendute in diverse date, che genera proventi lordi cumulativi riportati nel fascicolo. L’azienda ha 128.209.410 azioni in circolazione, fornendo contesto alla scala di queste transazioni rispetto al flottante.
Surgery Partners, Inc. (SGRY) Form 144 notice reporta una venta planificada de 18.134 acciones ordinarias a través de UBS el 29/09/2025 con un valor de mercado agregado de 399.822 dólares. El presentante indica que estas acciones fueron adquiridas el mismo día mediante un ejercicio de opción de acciones, y la venta propuesta se ejecutará en NASDAQ. El archivo/prevención detalla una extensa venta interna por parte de Wayne DeVeydt durante los tres meses previos, que totaliza 719.604 acciones vendidas en varias fechas, generando ingresos brutos acumulados reportados en el trámite. La empresa tiene 128.209.410 acciones en circulación, lo que contextualiza la magnitud de estas transacciones respecto al flotante.
Surgery Partners, Inc. (SGRY) Form 144 공고는 2025년 9월 29일 UBS를 통해 18,134주 보통주를 매도할 계획이며 총 시장가치는 399,822달러라고 보고합니다. 제출자는 이 주식들이 같은 날 주식매수선택권 행사로 취득되었으며 제안된 매도는 NASDAQ에서 실행될 예정이라고 밝힙니다. 제출서는 Wayne DeVeydt의 지난 3개월간의 광범위한 내부자 매도가 여러 날짜에 걸쳐 총 719,604주가 매도되었다고 목록화하고, 이는 보고서에 기재된 누적 총거래수익을 생성합니다. 회사의 발행주식 수는 128,209,410주로, 이러한 거래의 규모를 유통주식 대비 맥락화합니다.
Surgery Partners, Inc. (SGRY) avis Form 144 indique une vente planifiée de 18 134 actions ordinaires via UBS le 29/09/2025 d’une valeur marchande brute de 399 822 dollars. Le déposant indique que ces actions ont été acquises le même jour par exercice d’option d’achat, et la vente proposée sera exécutée sur le NASDAQ. Le dossier répertorie une vente interne étendue par Wayne DeVeydt au cours des trois derniers mois, totalisant 719 604 actions vendues à diverses dates, générant des produits bruts cumulatifs rapportés dans le dossier. L’entreprise compte 128 209 410 actions en circulation, ce qui fournit le contexte de l’ampleur de ces transactions par rapport au flottant.
Surgery Partners, Inc. (SGRY) Form 144 Hinweis meldet einen geplanten Verkauf von 18.134 Stammaktien über UBS am 29.09.2025 mit einem aggregierten Marktwert von 399.822 USD. Der Einreicher erklärt, dass diese Aktien am selben Tag durch eine Ausübung einer Aktienoption erworben wurden und der vorgeschlagene Verkauf an der NASDAQ durchgeführt wird. Die Einreichung listet umfangreiche Insider-Verkäufe von Wayne DeVeydt über die letzten drei Monate auf, insgesamt 719.604 Aktien, die in mehreren Terminen verkauft wurden und in dem Bericht ausgewiesene kumulierte Bruttoerlöse generieren. Das Unternehmen hat 128.209.410 ausstehende Aktien, was den Umfang dieser Transaktionen im Verhältnis zur Free Float-Größe kontextualisiert.
FAQ
What does the Form 144 for Surgery Partners (SGRY) report?
Who conducted significant sales disclosed in this filing?
How large is the company’s share base compared with these sales?
Were the acquired shares purchased or granted?
Does the Form 144 state whether a 10b5-1 plan governs these sales?
